Patents Issued in July 17, 2018
  • Patent number: 10023614
    Abstract: Peptide inhibitors of the interleukin-23 receptor, and related compositions and methods of using these peptide inhibitors to treat or prevent a variety of diseases and disorders, including inflammatory bowel disease, are disclosed.
    Type: Grant
    Filed: December 4, 2017
    Date of Patent: July 17, 2018
    Assignee: Protagonist Therapeutics, Inc.
    Inventors: Ashok Bhandari, Gregory Bourne, Xiaoli Cheng, Brian Troy Frederick, Jie Zhang, Dinesh V. Patel, David Liu
  • Patent number: 10023615
    Abstract: The present invention relates to the use of specific transporter cargo conjugate molecules for the transport of a substance of interest (cargo molecule) into white blood cells. Said transporter cargo conjugate molecules may be used for the treatment, prophylaxis, attenuation and/or amelioration of a disease and/or disorder involving white blood cells. The present invention also relates to manufacture of said transporter cargo conjugate molecules, to a method of transporting a substance of interest (cargo) into a white blood cell and to a white blood cell comprising said transporter cargo conjugate molecules or fragments thereof.
    Type: Grant
    Filed: December 22, 2009
    Date of Patent: July 17, 2018
    Assignee: Xigen Inflammation Ltd.
    Inventor: Christophe Bonny
  • Patent number: 10023616
    Abstract: The present invention relates to compositions comprising Haemophilus influenzae Protein E and Pilin A. More particularly, the present application relates to fusion proteins and immunogenic compositions comprising Protein E and PilA, vaccines comprising such immunogenic compositions and therapeutic uses of the same.
    Type: Grant
    Filed: February 18, 2016
    Date of Patent: July 17, 2018
    Assignee: GlaxoSmithKline Biologicals SA
    Inventors: Normand Blais, Steve Labbe, Jan Poolman
  • Patent number: 10023617
    Abstract: Methods and systems for efficient and cost-effective production of lantibiotics. The methods and systems are capable of producing lantibiotics having high purity suitable for pharmaceutical use.
    Type: Grant
    Filed: January 11, 2018
    Date of Patent: July 17, 2018
    Assignee: ImmuCell Corporation
    Inventors: Joseph H. Crabb, John W. Zinckgraf, Hanna Froebe
  • Patent number: 10023618
    Abstract: The invention provides an improved host strain for production of desired protein.
    Type: Grant
    Filed: August 15, 2017
    Date of Patent: July 17, 2018
    Assignee: Albumedix A/S
    Inventors: Christopher John Arthur Finnis, Jennifer Mary Mclaughlan, Per Kristoffer Nordeide, Preethi Ramaiya
  • Patent number: 10023619
    Abstract: Methods for the production of synthetic spider silk-like proteins in corn endosperm, plant leaf or plant shoot tissue are provided. The present invention provides further methods for the identification of synthetic spider silk-like proteins in corn endosperm, plant leaf or plant shoot tissue.
    Type: Grant
    Filed: March 27, 2015
    Date of Patent: July 17, 2018
    Assignee: University of Wyoming
    Inventors: Randolph V. Lewis, David J. Perry
  • Patent number: 10023620
    Abstract: The present disclosure provides a polypeptide and method for treating and/or preventing nephrotic syndrome, such as but not limited to those associated with minimal change disease and membranous nephropathy, and conditions related to nephrotic syndrome, such as but not limited to, proteinuria and edema, as well as diabetic nephropathy, diabetes mellitus, lupus nephritis or primary glomerular disease. The present disclosure further provides methods for reducing proteinuria and other disease states as discussed herein. Such methods comprise the therapeutic delivery of an Angptl4 polypeptide or Angptl4 polypeptide derivative to a subject.
    Type: Grant
    Filed: September 15, 2015
    Date of Patent: July 17, 2018
    Inventor: Sumant S Chugh
  • Patent number: 10023621
    Abstract: The disclosure provides, in part, follistatin polypeptides that are suitable for use in local administration and methods for use.
    Type: Grant
    Filed: June 4, 2015
    Date of Patent: July 17, 2018
    Assignee: ACCELERON PHARMA INC.
    Inventors: Ravindra Kumar, Asya Grinberg
  • Patent number: 10023622
    Abstract: The invention provides monomeric and oligomeric amyloid beta peptide isomers that are resistant towards fibrillogenesis and their use as screening reagents or antigens in methods and pharmaceutical preparations for the treatment of Alzheimer's disease and other conditions related to protein misfolding. The invention further provides transgenic animals expressing modified amyloid precursor proteins or amyloid beta peptides.
    Type: Grant
    Filed: May 19, 2017
    Date of Patent: July 17, 2018
    Assignee: ALZINOVA AB
    Inventors: Torleif Härd, Anders Sandberg
  • Patent number: 10023623
    Abstract: The present invention provides fusion proteins comprising a mucin-domain polypeptide covalently linked to an active protein that has improved properties (e.g. pharmacokinetic and/or physicochemical properties) compared to the same active protein not linked to mucin-domain polypeptide, as well as methods for making and using the fusion proteins of the invention.
    Type: Grant
    Filed: September 1, 2015
    Date of Patent: July 17, 2018
    Assignee: Alkermes, Inc.
    Inventors: Juan Alvarez, Jean Chamoun, Heather C. Losey
  • Patent number: 10023624
    Abstract: Recombinant Fc fusion proteins of human follicle-stimulating hormone (hFSH) with in vivo biological activities comparable to those of human follicle-stimulating hormone are disclosed. A recombinant hFSH-Fc fusion protein comprises ? subunit of hFSH (hFSH ?), CTP, ? subunit of hFSH (hFSH ?), a flexible peptide linker, and human IgG2 Fc variant (vIgG2Fc). A method is also disclosed to make such fusion proteins at good expression levels. These recombinant hFSH-Fc fusion proteins of the present disclosure exhibit sufficient biological activities and prolonged plasma half-lives, leading to improved pharmacokinetics and pharmacodynamics. Thus, a lower dosage may be used and/or better or different therapeutic efficacies with less side effects may be achieved. A method for the application of the recombinant hFSH-Fc fusion proteins in the treatment and/or prevention of human infertility is also disclosed.
    Type: Grant
    Filed: August 22, 2014
    Date of Patent: July 17, 2018
    Assignee: UnicoHealth Co. Ltd.
    Inventors: Yongmin Hou, Qiang Li, Maobo Wu, Sha Liao, Yujie Zhang, Zhenqi Xu
  • Patent number: 10023625
    Abstract: T cell receptors (TCRs) that have higher affinity for the Survivin antigen are provided. The high affinity TCRs were engineered through the generation of mutational libraries of TCRs in a single-chain format, followed by selection for improved stability and affinity on the surface of yeast (i.e. directed evolution). In embodiments, the engineered TCRs can be used in soluble form for targeted delivery in vivo, or as genes introduced into T cells in an adoptive T cell setting.
    Type: Grant
    Filed: November 21, 2014
    Date of Patent: July 17, 2018
    Assignee: THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS
    Inventors: Sheena N. Smith, Daniel T. Harris, David M. Kranz
  • Patent number: 10023626
    Abstract: The invention relates to compositions and methods for the preparation, manufacture and therapeutic use of polynucleotide molecules encoding at least one polypeptide of interest to modulate the immune response.
    Type: Grant
    Filed: September 30, 2014
    Date of Patent: July 17, 2018
    Assignee: ModernaTX, Inc.
    Inventors: Joseph Beene Bolen, Joshua P. Frederick
  • Patent number: 10023627
    Abstract: The present invention relates to a fusion protein binding to a vascular endothelial growth factor (VEGFR) and/or a placental growth factor (PIGF). The fusion protein of the present invention comprises (a) a Fc domain of IgG1, wherein two heavy chains are linked by disulfide bond, and (b) four immunoglobulin domain2s of the VEGFR1, wherein two immunoglobulin domain2s are sequentially fused to each heavy chain of the Fc domain of (a). The present fusion protein has excellent activities of inhibiting cell migration and cell invasion, and has highly enhanced growth inhibition effects to various carcinomas and fibroblasts. Therefore, The fusion protein of the present invention can be used in the preparation of an agent for treating cancers or ocular diseases.
    Type: Grant
    Filed: April 24, 2017
    Date of Patent: July 17, 2018
    Assignee: KOREA PRIME PHARM CO., LTD.
    Inventors: Daeik Kim, Inra Seo
  • Patent number: 10023628
    Abstract: The present invention provides cell lines for producing single chain FVIII polypeptides, e.g., chimeric single chain FVIII polypeptides, methods of producing single chain FVIII polypeptides, single chain FVIII polypeptides, and methods of treating Hemophilia A with a single chain Factor VIII polypeptide.
    Type: Grant
    Filed: July 5, 2013
    Date of Patent: July 17, 2018
    Assignee: Bioverativ Therapeutics Inc.
    Inventors: Susan Low, Jennifer A. Dumont, Alan J. Bitonti
  • Patent number: 10023629
    Abstract: The present invention relates to an antibody that confers protection against influenza virus infection. More specifically, it relates to an anti-neuraminidase antibody, protecting against highly pathogenic H5N1 influenza strains. The invention relates further to the use of the antibody for prophylactic and/or therapeutic treatment of influenza virus infections, and to a pharmaceutical composition comprising the antibody.
    Type: Grant
    Filed: December 11, 2013
    Date of Patent: July 17, 2018
    Assignees: VIB VZW, UNIVERSITEIT GENT, VRIJE UNIVERSITEIT BRUSSEL
    Inventors: Xavier Saelens, Francisco Miguel Lopez Cardoso, Ann DePicker, Serge Muyldermans
  • Patent number: 10023630
    Abstract: An objective of the invention is to provide anti-C5 antibodies and methods of using the same. The invention provides anti-C5 antibodies and methods of using the same. In some embodiments, an isolated anti-C5 antibody of the present invention binds to an epitope within the ? chain of C5 with a higher affinity at neutral pH than at acidic pH. The invention also provides isolated nucleic acids encoding an anti-C5 antibody of the present invention. The invention also provides host cells comprising a nucleic acid of the present invention. The invention also provides a method of producing an antibody comprising culturing a host cell of the present invention so that the antibody is produced. The invention further provides a method of producing an anti-C5 antibody comprising immunizing an animal against a polypeptide which comprises the MG1-MG2 domain of the ? chain of C5. Anti-C5 antibodies of the present invention may be for use as a medicament.
    Type: Grant
    Filed: August 28, 2017
    Date of Patent: July 17, 2018
    Assignee: CHUGAI SEIYAKU KABUSHIKI KAISHA
    Inventors: Yoshinao Ruike, Zenjiro Sampei
  • Patent number: 10023631
    Abstract: A serum albumin binding antibody or fragment thereof comprising a heavy chain variable domain having the sequence given in SEQ ID NO: 1 or SEQ ID NO:2 and/or comprising a light chain variable domain having the sequence given in SEQ ID NO:3 or SEQ ID NO:4, in particular comprising a heavy chain variable domain and a light chain variable domain having the sequence given in SEQ ID NO: 1 and SEQ ID NO:3 or a heavy chain variable domain and a light chain variable domain having the sequence given in SEQ ID NO: 2 and SEQ ID NO:4. The disclosure also extends to polynucleotides encoding the antibodies or fragments, vectors comprising same and host cells capable of expressing the polynucleotides. The disclosure further includes pharmaceutical compositions comprising the antibodies or fragments and therapeutic used of any one of the same.
    Type: Grant
    Filed: October 27, 2017
    Date of Patent: July 17, 2018
    Assignee: UCB Biopharma SPRL
    Inventors: Ralph Adams, Pallavi Bhatta, Sam Philip Heywood, David Paul Humphreys
  • Patent number: 10023632
    Abstract: Hybridoma lines that secrete human monoclonal antibodies with high binding specificity and biological activity, particularly neutralizing activity against granulocyte-macrophage colony stimulating factor, and methods of generating the hybridoma lines are provided. Target antigens and epitopes are also provided. The antibodies may be used in therapeutic methods, for example in the treatment of cancer, infectious disease, or autoimmune disease.
    Type: Grant
    Filed: July 18, 2016
    Date of Patent: July 17, 2018
    Assignee: Morphotek, Inc.
    Inventors: Philip M. Sass, Nicholas C. Nicolaides, Luigi Grasso, Wolfgang Ebel, Jian Li, Qimin Chao, Eric Routhier
  • Patent number: 10023633
    Abstract: The present invention relates to a method for generating immunoglobulin sequences against cell-associated antigens, more particularly, antigens that are membrane-anchored. The invention also provides immunoglobulin sequences obtainable by the method of the invention. Specifically, the present invention relates to the generation of immunoglobulin sequences by use of DNA vaccination. More specifically, the present invention relates to generation of immunoglobulin sequences in camelids, preferably directed against cell-associated antigens, in particular antigens with multiple transmembrane spanning domains, including GPCRs and ion channels, by DNA vaccination. Furthermore, the present invention relates to said immunoglobulin sequences against cell-associated antigens, more particularly, antigens that are membrane-anchored, such as e.g. GPCRs and ion channels, more preferably ion channels.
    Type: Grant
    Filed: February 10, 2016
    Date of Patent: July 17, 2018
    Assignee: Ablynx N.V.
    Inventors: Toon Laeremans, Catelijne Stortelers, Friedrich Nolte, Maria Gonzalez Pajuelo, Joana Assunção, Philippe Van Rompaey
  • Patent number: 10023634
    Abstract: Provided herein are antibodies, or antigen-binding portions thereof, that bind to T-cell immunoglobulin and mucin-domain containing-3 (TIM3) protein. Also provided are uses of these antibodies, or antigen-binding portions thereof, in therapeutic applications, such as treatment of cancer. Further provided are cells that produce the antibodies, or antigen-binding portions thereof, polynucleotides encoding the heavy and/or light chain regions of the antibodies, or antigen-binding portions thereof, and vectors comprising the polynucleotides encoding the heavy and/or light chain regions of the antibodies, or antigen-binding portions thereof.
    Type: Grant
    Filed: July 13, 2017
    Date of Patent: July 17, 2018
    Assignee: Bristol-Myers Squibb Company
    Inventors: Xiao Min Schebye, Mark J. Selby, Michelle Minhua Han, Christine Bee, Andy X. Deng, Anan Chuntharapai, Brigitte Devaux, Huiming Li, Paul O. Sheppard, Alan J. Korman, Daniel F. Ardourel, Ekaterina Deyanova, Richard Huang, Guodong Chen, Michelle Kuhne, Hong-An Troung
  • Patent number: 10023635
    Abstract: Provided herein are various embodiments relating to antibodies. Some of the embodiments include agonist antibodies that bind ICOS. Such antibodies can be used in methods to treat, for example, cancer.
    Type: Grant
    Filed: March 22, 2016
    Date of Patent: July 17, 2018
    Assignee: Jounce Therapeutics, Inc.
    Inventors: Stephen Sazinsky, Jennifer S. Michaelson, Sriram Sathyanarayanan, Kutlu Goksu Elpek
  • Patent number: 10023636
    Abstract: The present invention provides caninized murine anti-human PD-1 antibodies that have specific sequences and a high binding affinity for canine PD-1. The invention also relates to use of these antibodies in the treatment of dogs.
    Type: Grant
    Filed: December 19, 2014
    Date of Patent: July 17, 2018
    Assignee: Intervet Inc.
    Inventors: Mohamad Morsey, Yuanzheng Zhang, Denise Bartels-Morozov, Jason Erskine, Ian Tarpey, Leonard G. Presta
  • Patent number: 10023637
    Abstract: Agonists to ICOS in combination with a blocking agent to a T cell inhibitory receptor (e.g., CTLA-4, PD-1, etc.) are demonstrated herein to be useful for the treatment of tumors.
    Type: Grant
    Filed: May 3, 2016
    Date of Patent: July 17, 2018
    Assignees: Board of Regents, The University of Texas System, Memorial Sloan-Kettering Cancer Center
    Inventors: James Allison, Padmanee Sharma, Sergio A. Quezada, Tihui Fu
  • Patent number: 10023638
    Abstract: The current invention provides human variable chain framework regions and humanized antibodies comprising the framework regions, the antibodies being specific for integrin ?1. The invention also provides methods for utilizing the antibodies, for example to treat diseases such as cancer.
    Type: Grant
    Filed: December 24, 2013
    Date of Patent: July 17, 2018
    Assignee: Oncosynergy, Inc.
    Inventor: W. Shawn Carbonell
  • Patent number: 10023639
    Abstract: Multi-functional antibody polypeptide comprises: (a) a first functional domain, specifically recognizing a cryptic epitope formed by 287th to 302nd amino acid sequence of the EGFR, shown as SEQ ID NO:1, and (b) a second functional domain, specifically recognizing the surface antigen of a human T cell.
    Type: Grant
    Filed: March 4, 2013
    Date of Patent: July 17, 2018
    Assignee: CARSGEN THERAPEUTICS CO., LTD.
    Inventors: Zonghai Li, Hua Jiang, Bizhi Shi, Huamao Wang, Juan Kong, Huiping Gao
  • Patent number: 10023640
    Abstract: The invention relates to antibodies that bind to VEGFR-2. The antibodies are used for treating neoplastic diseases, hyperproliferative disorders, and angiogenic disorders and can be used alone or in combination with other agents.
    Type: Grant
    Filed: October 7, 2013
    Date of Patent: July 17, 2018
    Assignee: KADMON CORPORATION, LLC
    Inventors: Zhenping Zhu, Dan Lu, Zhanna Polonskaya
  • Patent number: 10023641
    Abstract: The present invention provides antibodies that bind to Tie2 and methods of using same. According to certain embodiments of the invention, the antibodies are fully human antibodies that bind to human Tie2 and block the interaction between Tie2 and one or more Tie2 ligands such as angiopoietin 1 (Ang1), angiopoietin 2 (Ang2), angiopoietin 3 (Ang3) and/or angiopoietin 4 (Ang4). The antibodies of the invention are useful, inter alia, for the treatment of diseases and disorders associated with one or more Tie2 biological activities including angiogenesis.
    Type: Grant
    Filed: December 9, 2016
    Date of Patent: July 17, 2018
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventor: Gavin Thurston
  • Patent number: 10023642
    Abstract: The present invention provides antibodies that bind to platelet derived growth factor receptor beta (PDGFR-beta) and methods of using the same. According to certain embodiments of the invention, the antibodies are fully human antibodies that bind to human PDGFR-beta with high affinity. The antibodies of the invention are useful for the treatment of diseases and disorders associated with PDGFR-beta signaling and/or PDGFR-beta cellular expression, such as ocular diseases, fibrotic diseases, vascular diseases and cancer.
    Type: Grant
    Filed: April 6, 2017
    Date of Patent: July 17, 2018
    Assignee: REGENERON PHARMACEUTICALS, INC.
    Inventors: Stanley J. Wiegand, Ivan B. Lobov
  • Patent number: 10023643
    Abstract: The present invention relates to antibodies against human CSF-1R (CSF-1R antibody), methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.
    Type: Grant
    Filed: December 12, 2012
    Date of Patent: July 17, 2018
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Georg Fertig, Alexander Fidler, Klaus Kaluza, Carola Ries, Stefan Seeber, Marlene Thomas
  • Patent number: 10023644
    Abstract: The present invention provides antibodies and antigen-binding fragments of antibodies that bind to leptin receptor (LEPR), and methods of using the same. According to certain embodiments, the invention includes antibodies and antigen-binding fragments of antibodies that bind LEPR and activate LEPR signaling. In other embodiments, the invention includes antibodies and antigen-binding fragments of antibodies that bind to LEPR and enhance sensitization of LEPR to an antigen. In certain embodiments, the invention includes antibodies and antigen-binding fragments of antibodies that bind LEPR in the presence and absence of leptin. In certain embodiments, the invention includes antibodies and antigen-binding fragments of antibodies that induce signaling in cells expressing LEPR mutants that otherwise exhibit defective or impaired signaling in the presence of leptin.
    Type: Grant
    Filed: October 11, 2016
    Date of Patent: July 17, 2018
    Assignee: REGENERON PHARMACEUTICALS, INC.
    Inventors: Jesper Gromada, Panayiotis Stevis, Judith Altarejos
  • Patent number: 10023645
    Abstract: The present disclosure provides novel anti-CD40 antibodies, compositions including the new antibodies, nucleic acids encoding the antibodies, and methods of making and using the same.
    Type: Grant
    Filed: February 21, 2018
    Date of Patent: July 17, 2018
    Assignee: AbbVie Biotherapeutics Inc.
    Inventors: Diane Sau Mun Cohen, Diane Hollenbaugh, Shiming Ye
  • Patent number: 10023646
    Abstract: This invention provides monoclonal antibodies that recognize the Toll-like Receptor 4/MD-2 receptor complex, and monoclonal antibodies that recognize the TLR4/MD2 complex as well as TLR4 when not complexed with MD-2. The invention further provides methods of using the monoclonal antibodies as therapeutics. This invention also provides soluble chimeric proteins, methods of expressing and purifying soluble chimeric proteins, and methods of using soluble chimeric proteins as therapeutics, in screening assays and in the production of antibodies.
    Type: Grant
    Filed: January 5, 2017
    Date of Patent: July 17, 2018
    Assignee: NovImmunie S.A.
    Inventors: Greg Elson, Olivier Leger
  • Patent number: 10023647
    Abstract: Provided herein are polypeptides that are capable of crossing the cellular membrane and entering into the intracellular environment, which polypeptides are suitable for use in prophylactic, therapeutic or diagnostic applications as well as in screening and detection. Nucleic acids encoding such polypeptides; methods for preparing such polypeptides, host cells expressing or capable of expressing such polypeptides, compositions, and in particular pharmaceutical compositions, that comprise such polypeptides, in particular for prophylactic, therapeutic or diagnostic purposes are also provided.
    Type: Grant
    Filed: October 22, 2013
    Date of Patent: July 17, 2018
    Assignee: COMPLIX NV
    Inventors: Stefan Loverix, Philippe Alard, Sabrina Deroo, Klaartje Somers, Ignace Lasters, Johan Desmet
  • Patent number: 10023648
    Abstract: In a first aspect, the present invention relates to genetically modified T-cells having a chimeric antigen receptor (CAR) in a method for adoptive cell therapy for treating TOSO+ cancer, like B-cell leukemia/lymphoma, in a subject in need thereof. In particular, the present invention relates to a genetically engineered T-cell containing and expressing a specific chimeric antigen receptor being toxic to TOSO+ cancer cells while being less toxic or non-toxic to TOSO+ non-cancer cells, in particular, being non-toxic to normal B cells and its precursors. In a further aspect, the present invention relates to a specific chimeric antigen receptor and the nucleic acid molecule encoding the same as well as vectors and cells containing the same.
    Type: Grant
    Filed: May 27, 2016
    Date of Patent: July 17, 2018
    Inventors: Andreas Hombach, Elena Faitschuk, Hinrich Abken
  • Patent number: 10023649
    Abstract: The present disclosure describes combination therapies comprising an antibody which specifically binds to human CCR4 and a selective 4-1BB agonist, and the use of the combination therapies for the treatment of cancer.
    Type: Grant
    Filed: May 15, 2015
    Date of Patent: July 17, 2018
    Assignees: Pfizer Inc., Kyowa Hakko Kirin Co., Ltd.
    Inventors: Chia-Yang Lin, Shihao Chen, LiFen Lee, Shobha Potluri, Denis Healy, Margaret Marshall, Naoki Sawada
  • Patent number: 10023650
    Abstract: The present invention provides for recombinant monoclonal antibodies that bind to human colorectal and pancreatic carcinoma-associated antigens, along with nucleic acid sequences encoding the antibody chains, and the amino acid sequences corresponding to the nucleic acids, and uses for these antibodies, nucleic acids and amino acids.
    Type: Grant
    Filed: May 19, 2016
    Date of Patent: July 17, 2018
    Assignee: PRECISION BIOLOGICS, INC.
    Inventors: J. Andrew Bristol, Judith A. Kantor
  • Patent number: 10023651
    Abstract: Provided are humanized monoclonal antibodies (mAbs) or fragments thereof that bind with specificity to the Thomsen-Friedenreich (TF) human tumor antigen. Three distinct variable heavy and three variable light chains are provided, and can be combined to make a total of twenty-five distinct heavy and light chain combinations. Methods of using the mAbs and fragments thereof for cancer therapy and diagnostic imaging are provided, as are methods for making the mAbs and fragments thereof. In vitro cell cultures that express the mAbs and fragments thereof, and kits are also provided.
    Type: Grant
    Filed: October 18, 2016
    Date of Patent: July 17, 2018
    Assignee: THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK
    Inventors: Kate Rittenhouse-Olson, Julia Abdullah, Jing Ying Eng, Stephen T. Koury
  • Patent number: 10023652
    Abstract: The present disclosure relates to a method of inhibiting tumor growth. More specifically, the present disclosure relates to the use of monoclonal antibodies for targeting truncated O-glycans on glycoproteins to inhibit activation of pro-survival ceil signaling pathways, to inhibit tumor growth. For example, monoclonal antibody AR9.6 may be used to target truncated O-glycans on the MUC16 glycoprotein, thereby inhibiting the phosphatidyiinositol 3-kinase/Akt (Pi3K/Akt) signaling pathway.
    Type: Grant
    Filed: June 24, 2014
    Date of Patent: July 17, 2018
    Assignee: Board of Regents of the University of Nebraska
    Inventors: Michael Anthony Hollingsworth, Prakash Radhakrishnan
  • Patent number: 10023653
    Abstract: Expression of proteolytically active, high molecular weight ADAM protease is relatively increased in tumor cells that also express the putative tumor stem cell marker CD133. An antibody or antibody fragment such as 8C7 monoclonal antibody may be used to selectively bind to proteolytically active, high molecular weight ADAM10 protease to thereby detect tumor cells and also as a therapeutic agent for treating cancers, tumors and other malignancies inclusive of leukemia, lymphoma, lung cancer, colon cancer, adenoma, neuroblastoma, brain tumor, renal tumor, prostate cancer, sarcoma and/or melanoma.
    Type: Grant
    Filed: February 4, 2015
    Date of Patent: July 17, 2018
    Assignees: Monash University, Memorial Sloan-Kettering Cancer Centre, Ludwig Institute for Cancer Research Ltd.
    Inventors: Martin Lackmann, Peter W. Janes, Lakmali Atapattu Mudiyanselage, Andrew M. Scott, Dimitar B. Nikolov, Nayanendu Saha
  • Patent number: 10023654
    Abstract: An human antibody or antigen-binding fragment of a human antibody that specifically binds and inhibits human proprotein convertase subtilisin/kexin type 9 (hPCSK9) characterized by the ability to reduce serum LDL cholesterol by 40-80% over a 24, 60 or 90 day period relative to predose levels, with little or no reduction in serum HDL cholesterol and/or with little or no measurable effect on liver function, as determined by ALT and AST measurements.
    Type: Grant
    Filed: December 13, 2016
    Date of Patent: July 17, 2018
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Mark W. Sleeman, Joel H. Martin, Tammy T. Huang, Douglas MacDonald
  • Patent number: 10023655
    Abstract: We provide new monoclonal antibody inhibitors of coagulases for treatment of S. aureus. The monoclonal antibodies are useful in targeting the SC N-terminus and inhibiting SC-ProT activation. The monoclonal antibodies are able to bind to and interfere with, modulate, and/or inhibit the binding interactions between the staphylocoagulase protein and its ligand protein prothrombin in blood and tissues. The antibodies are effective in inhibiting the activation of prothrombin.
    Type: Grant
    Filed: May 1, 2017
    Date of Patent: July 17, 2018
    Inventor: William R Church
  • Patent number: 10023656
    Abstract: The present invention relates to blocking, inhibiting, reducing, antagonizing or neutralizing the activity of IL-17A and IL-17F. IL-17A and IL-17F are cytokines that are involved in inflammatory processes and human disease. The present invention includes antibodies that bind both IL-17A and IL-17F, as well as methods of using the same in inflammation.
    Type: Grant
    Filed: April 28, 2017
    Date of Patent: July 17, 2018
    Assignee: ZYMOGENETICS INC.
    Inventors: Stephen R. Jaspers, Scott R. Presnell
  • Patent number: 10023657
    Abstract: Some aspects of this invention are based on the recognition that reversible protein multimers in which monomeric proteins are conjugated to a carrier molecule via chelation complex bonds are stable under physiological conditions and can be dissociated in a controlled manner under physiological, nontoxic conditions. Accordingly, such protein multimers are useful for a variety of in vitro, ex vivo, and in vivo application for research, diagnostics, and therapy. Some aspect of this invention provide reversible MHC protein multimers, and methods of using such multimers in the detection and/or isolation of specific T-cells or T-cell populations. Because reversible MHC multimers can efficiently be dissociated, the time of MHC binding to T-cell receptors, and, thus, T-cell receptor-mediated T-cell activation can be minimized.
    Type: Grant
    Filed: September 30, 2011
    Date of Patent: July 17, 2018
    Assignee: Ludwig Institute for Cancer Research Ltd.
    Inventors: Immanuel F. Luescher, Julien Schmidt, Philippe Guillaume, Danijel Dojcinovic
  • Patent number: 10023658
    Abstract: The invention relates to conjugates of hyaluronic acid oligomer according to the general formulae I, II III or IV, or a salt thereof, the method of preparation thereof and use thereof, where the oligomer is bonded to the respective substrate by its ending anomeric center via a bi-functional amino linker by means of an amino or imino bond. This type of conjugates allows releasing oligomers in their native form. The prepared systems exhibited an enhanced biological activity against selected lines of cancer cells.
    Type: Grant
    Filed: March 10, 2015
    Date of Patent: July 17, 2018
    Assignee: Contipro a.s.
    Inventors: Radovan Buffa, Ivana Basarabova, Kristina Nesporova, Tereza Ehlova, Ondrej Kotland, Petra Sedova, Leos Hromek, Vladimir Velebny
  • Patent number: 10023659
    Abstract: The present invention relates to a process for the production of heparin derivatives having an average molecular weight of from about 4.6 to about 6.9 kDa and an anti-factor Xa activity of less than about 10 IU/mg, comprising the steps of oxidation of unfractionated heparin, depolymerisation and reduction of resulting terminal groups.
    Type: Grant
    Filed: June 19, 2014
    Date of Patent: July 17, 2018
    Assignee: Dilafor AB
    Inventors: Per-Olov Eriksson, Erik Yngve Holmer
  • Patent number: 10023660
    Abstract: Provided herein are organic solvent-based processes for the isolation of purified natural rubber from non-Hevea plants. The processes are particularly useful with plant matter that comprises at least 90% by weight roots sourced from Taraxacum kok-saghyz (Russian dandelion), Scorzonera tau-saghyz (Tau-Saghyz), Scorzonera uzbekistanica, and combinations thereof. Also provided herein is a purified non-Hevea rubber product containing 100 phr of rubber sourced from Taraxacum kok-saghyz, Scorzon-era tau-saghyz, Scorzonera uzbekistanica, and combinations thereof, having a specified purity level. Additionally provided are sulfur-vulcanizable rubber compounds and sulfur-vulcanized rubber compounds that incorporate 10-100 phr of purified non-Hevea rubber product sourced from Taraxacum kok-saghyz, Scorzonera tau-saghyz, Scorzonera uzbekistanica, and combinations thereof, having a specified purity level.
    Type: Grant
    Filed: May 16, 2013
    Date of Patent: July 17, 2018
    Assignee: Bridgestone Corporation
    Inventors: Amy M. Randall, Arif O. Gozen
  • Patent number: 10023661
    Abstract: Disclosed are a modified conjugated diene-based polymer, a method of preparing the same, and a rubber composition including the same.
    Type: Grant
    Filed: September 18, 2015
    Date of Patent: July 17, 2018
    Assignee: LG Chem, Ltd.
    Inventors: Jin-Young Kim, Ro-Mi Lee, No-Ma Kim
  • Patent number: 10023662
    Abstract: A new and efficient toxicity and/or odor reducing method for ethyl acrylate and/or acrylonitrile containing aqueous polymer dispersion is disclosed, which comprises contacting a sufficient amount of an ethyl acrylate/acrylonitrile scavenging compound with a stable aqueous dispersion of a polymer to form a polymeric dispersion that contains less than 1 ppm of ethyl acrylate and less than 1 ppm acrylonitrile; wherein the polymer contains a) polymerized units of acylonitrile and/or ethyl acrylate and b) at least 5 ppm of ethyl acrylate and/or acrylonitrile monomers; and wherein the ethyl acrylate/acrylonitrile scavenging compound are contacted with the dispersion independently from contact of the dispersion with any redox pairs.
    Type: Grant
    Filed: November 2, 2016
    Date of Patent: July 17, 2018
    Assignees: Dow Global Technologies LLC, Rohm and Haas Company
    Inventors: Tingke Zhang, Jitao Chen, Minghe Li
  • Patent number: 10023663
    Abstract: Propylene polymers having a melt flow index in the range from 3.0 dg/min to 8.0 dg/min can be particularly suited for high-tenacity fibers and yarns and nonwovens. The propylene polymers can be produced by a process that includes polymerizing propylene or propylene and at least one comonomer in presence of a Ziegler-Natta polymerization catalyst, an aluminium alkyl, and hydrogen.
    Type: Grant
    Filed: June 27, 2013
    Date of Patent: July 17, 2018
    Assignee: TOTAL RESEARCH & TECHNOLOGY FELUY
    Inventors: Peter Geeurickx, Alain Standaert, Jean-Luc Zuliani